NCT05789745View on ClinicalTrials.gov

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

May 24, 2023

Study Completion Date

May 24, 2023

Conditions
VolunteersHealthy
Interventions
DRUG

Recombinant human plasma gelsolin

intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours

OTHER

placebo

intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours

Trial Locations (1)

55114

Nucleus Network, Saint Paul

Sponsors
All Listed Sponsors
lead

BioAegis Therapeutics Inc.

INDUSTRY